Name: Real World Evidence Solutions Market by Component (Datasets (Claims, Clinical, Pharmacy, Genomics), Application (Drug/Device Development (Cancer, Cardio, Neuro), Reimbursement), End User (Pharma, Medtech, Payers, Provider), Region - Global Forecast to 2030
Brand: MarketsandMarkets
SKU: HIT6444
Price: 4950 USD
Availability: InStock

1 INTRODUCTION 35 1.1 STUDY OBJECTIVES 35 1.2 MARKET DEFINITION 35 1.3 STUDY SCOPE 36 1.3.1 MARKET SEGMENTATION 36 1.3.2 INCLUSIONS & EXCLUSIONS 37 1.4 YEARS CONSIDERED 38 1.5 CURRENCY CONSIDERED 38 1.6 STAKEHOLDERS 38 1.7 SUMMARY OF CHANGES 39 2 RESEARCH METHODOLOGY 40 2.1 RESEARCH DATA 40 2.1.1 SECONDARY DATA 41 2.1.1.1 Key data from secondary sources 42 2.1.2 PRIMARY DATA 43 2.1.2.1 Key data from primary sources 44 2.1.2.2 Key industry insights 45 2.2 RESEARCH METHODOLOGY DESIGN 46 2.3 MARKET SIZE ESTIMATION 47 2.3.1 BOTTOM-UP APPROACH 48 2.3.2 TOP-DOWN APPROACH 48 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 51 2.5 RESEARCH ASSUMPTIONS 52 2.6 RISK ASSESSMENT 52 2.7 LIMITATIONS 53 2.7.1 SCOPE-RELATED LIMITATIONS 53 2.7.2 METHODOLOGY-RELATED LIMITATIONS 53 3 EXECUTIVE SUMMARY 54 4 PREMIUM INSIGHTS 60 4.1 REAL WORLD EVIDENCE SOLUTIONS MARKET OVERVIEW 60 4.2 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER AND COUNTRY 61 4.3 REAL WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62 4.4 REGIONAL MIX: REAL WORLD EVIDENCE SOLUTIONS MARKET, 2025−2030 62 4.5 REAL WORLD EVIDENCE SOLUTIONS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES, 2025 VS. 2030 63 5 MARKET OVERVIEW 64 5.1 INTRODUCTION 64 5.2 MARKET DYNAMICS 64 5.2.1 DRIVERS 66 5.2.1.1 Rising geriatric population and subsequent increase in prevalence of chronic diseases 66 5.2.1.2 Shift from volume-based care to value-based care 66 5.2.1.3 Potential of real world evidence in reducing drug development costs and expediting drug development process 67 5.2.1.4 Increased R&D spending for development of new pharmaceutical products and medical devices 68 5.2.1.5 Support from regulatory bodies for use of real world evidence solutions 69 5.2.2 RESTRAINTS 69 5.2.2.1 Reluctance of medical practitioners and researchers to rely on real world studies 69 5.2.2.2 Data quality and standardization issues 70 5.2.3 OPPORTUNITIES 70 5.2.3.1 Growth opportunities in emerging markets 70 5.2.3.2 Increased focus on end-to-end RWE services 71 5.2.3.3 Increased focus on personalized and precision medicine 71 5.2.3.4 Market access, health technology assessment (HTA), and reimbursement 72 5.2.4 CHALLENGES 73 5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure 73 5.2.4.2 Shortage of skilled professionals 73 5.3 INDUSTRY TRENDS 74 5.3.1 EMERGING ROLE OF WEARABLE DEVICES 74 5.3.2 SOCIAL MEDIA-SOURCED RWE 74 5.3.3 RISING USE OF RWD AND RWE ACROSS PHARMACEUTICAL INDUSTRY 75 5.3.4 RWE ANALYTICS APPROACH: INTERNAL VS. OUTSOURCED 76 5.3.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE INTO RWD MANAGEMENT 77 5.4 REAL WORLD DATA SOURCES 77 5.5 ECOSYSTEM ANALYSIS 79 5.6 VALUE CHAIN ANALYSIS 82 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84 5.8 PORTER’S FIVE FORCES ANALYSIS 85 5.8.1 THREAT FROM NEW ENTRANTS 86 5.8.2 BARGAINING POWER OF SUPPLIERS 86 5.8.3 BARGAINING POWER OF BUYERS 86 5.8.4 THREAT FROM SUBSTITUTES 86 5.8.5 INTENSITY OF COMPETITIVE RIVALRY 86 5.9 PRICING ANALYSIS 87 5.9.1 INDICATIVE PRICING FOR REAL WORLD EVIDENCE SOLUTIONS, BY COMPONENT 87 5.9.2 INDICATIVE PRICING OF REAL WORLD EVIDENCE SOLUTIONS, BY REGION 88 5.10 TECHNOLOGY ANALYSIS 89 5.10.1 KEY TECHNOLOGIES 89 5.10.1.1 Use of AI and ML 89 5.10.1.2 Blockchain technology 90 5.10.2 ADJACENT TECHNOLOGIES 90 5.10.2.1 Predictive analytics 90 5.10.2.2 Visualization dashboard software 90 5.10.3 COMPLEMENTARY TECHNOLOGIES 91 5.10.3.1 Electronic health records (EHRs) 91 5.10.3.2 Clinical trial management system 91 5.11 TARIFF AND REGULATORY LANDSCAPE 92 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 5.11.2 REGULATORY ANALYSIS 93 5.11.2.1 North America 93 5.11.2.1.1 US 93 5.11.2.1.1.1 Use cases 94 5.11.2.1.2 Canada 94 5.11.2.2 Europe 95 5.11.2.3 Asia Pacific 95 5.11.2.3.1 China 95 5.11.2.3.2 Japan 96 5.11.2.3.3 India 96 5.11.2.4 Middle East & Africa 97 5.11.2.5 Latin America 97 5.12 PATENT ANALYSIS 97 5.12.1 PATENT PUBLICATION TRENDS FOR REAL WORLD EVIDENCE SOLUTIONS MARKET 97 5.12.2 JURISDICTION AND TOP APPLICANT ANALYSIS 98 5.13 KEY CONFERENCES & EVENTS 101 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 102 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 102 5.14.2 BUYING CRITERIA 103 5.15 CASE STUDY ANALYSIS 104 5.15.1 DESIGNING AND BUILDING RWE DASHBOARDS AND LEVERAGING EHR AND CLAIMS DATA 104 5.15.2 INTEGRATING SPECIALTY PHARMACY AND PATIENT HUB DATA WITH RWD DATA TO INVESTIGATE INTO NON-ADHERENCE FACTORS 104 5.15.3 SIMPLIFYING DATA ANALYTICS WITH RWE PLATFORM 105 5.16 END USER ANALYSIS 105 5.16.1 UNMET NEEDS 105 5.16.2 END USER EXPECTATIONS 106 5.17 REAL WORLD EVIDENCE SOLUTIONS MARKET: BUSINESS MODELS 107 5.17.1 PLATFORM-AS-A-SERVICE (PAAS) MODEL 107 5.17.2 DATA PROVIDER MODEL 107 5.17.3 CONSULTING AND SERVICES MODEL 107 5.17.4 COLLABORATIVE RESEARCH MODEL 107 5.18 INVESTMENT & FUNDING SCENARIO 108 5.19 IMPACT OF AI/GENERATIVE AI ON REAL WORLD EVIDENCE SOLUTIONS MARKET 108 5.19.1 TOP USE CASES & MARKET POTENTIAL 108 5.19.1.1 Key use cases 109 5.19.2 IMPLEMENTATION OF AI/GENERATIVE AI: CASE STUDIES 110 5.19.2.1 AI-powered RWE transformed patient targeting and treatment initiation 110 5.19.3 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT MARKET ECOSYSTEM 111 5.19.3.1 Electronic health record (EHR) market 111 5.19.3.2 Real world data (RWD) market 112 5.19.4 USER READINESS AND IMPACT ASSESSMENT 112 5.20 US TARIFF 2025 113 5.20.1 INTRODUCTION 113 5.20.2 KEY TARIFF RATES 114 5.20.3 PRICE IMPACT ANALYSIS 114 5.20.4 IMPACT ON COUNTRY/REGION 115 5.20.4.1 US 115 5.20.4.2 Europe 116 5.20.4.3 Asia Pacific 116 5.20.5 IMPACT ON END-USE INDUSTRIES 117 6 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT 118 6.1 INTRODUCTION 119 6.2 SERVICES 119 6.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND 119 6.3 DATA SETS 120 6.3.1 DISPARATE DATA SETS 121 6.3.1.1 Clinical settings data sets 122 6.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth 122 6.3.1.2 Claims data sets 123 6.3.1.2.1 Growing need to understand economic benefits of drug reimbursement by payers to drive growth 123 6.3.1.3 Pharmacy data sets 124 6.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth 124 6.3.1.4 Patient-powered data sets 125 6.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth 125 6.3.1.5 Registry-based data sets 126 6.3.1.5.1 Increasing number of disease registries to drive demand for registry-based data sets in evidence generation 126 6.3.1.6 Others 127 6.3.1.6.1 Increasing number of genomics registries to drive demand for RWE evidence solutions 127 6.3.2 INTEGRATED DATA SETS 128 6.3.2.1 Increasing demand for integrated data from multiple sources to drive growth 128 7 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION 129 7.1 INTRODUCTION 130 7.2 DRUG DEVELOPMENT & APPROVALS 130 7.2.1 ONCOLOGY 131 7.2.1.1 Growing number of clinical trials focused on cancer treatment to drive demand 131 7.2.2 CARDIOVASCULAR DISEASES 132 7.2.2.1 High prevalence of cardiovascular diseases to support market growth 132 7.2.3 NEUROLOGY 133 7.2.3.1 Rapidly aging global population and subsequent increase in prevalence of neurological disorders to drive growth 133 7.2.4 IMMUNOLOGY 134 7.2.4.1 Increasing focus on developing innovative products to drive growth 134 7.2.5 RARE DISEASES 135 7.2.5.1 Need for harnessing RWE to advance therapies for rare diseases to boost market 135 7.2.6 OTHER THERAPEUTIC AREAS 136 7.3 MEDICAL DEVICE DEVELOPMENT & APPROVALS 137 7.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND 137 7.4 POST-MARKET SURVEILLANCE 138 7.4.1 EXTENSIVE USE OF RWE SOLUTIONS IN POST-MARKET SURVEILLANCE TO BOOST MARKET 138 7.5 MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING 139 7.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS TO FAVOR MARKET GROWTH 139 7.6 CLINICAL & REGULATORY DECISION-MAKING 140 7.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS TO DRIVE USE OF RWE SOLUTIONS 140 7.7 OTHER APPLICATIONS 141 8 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL 143 8.1 INTRODUCTION 144 8.2 PAY-PER-USAGE (VALUE-BASED PRICING) 144 8.2.1 RISING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE SOLUTIONS TO BOOST MARKET 144 8.3 SUBSCRIPTION 145 8.3.1 RISING PREFERENCE FOR FLEXIBILITY AND SCALABILITY TO SUPPORT MARKET GROWTH 145 8.4 LICENSE 146 8.4.1 FOCUS ON ENABLING END-TO-END RWE DELIVERY THROUGH PLATFORM LICENSING TO DRIVE MARKET 146 9 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE 148 9.1 INTRODUCTION 149 9.2 ON-PREMISES 149 9.2.1 NEED FOR ENHANCED DATA CONTROL BENEFITS TO BOOST DEMAND 149 9.3 CLOUD-BASED 150 9.3.1 INCREASED SCALABILITY AND FLEXIBILITY IN DATA COLLECTION TO DRIVE GROWTH 150 9.4 HYBRID 151 9.4.1 EMPHASIS ON INCREASED SCALABILITY AND FLEXIBILITY IN DATA COLLECTION TO DRIVE GROWTH 151 10 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER 152 10.1 INTRODUCTION 153 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 153 10.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH 153 10.3 MEDTECH COMPANIES 154 10.3.1 NEED FOR ACCELERATING MEDTECH MARKET ACCESS VIA REAL WORLD EVIDENCE SOLUTIONS TO BOOST GROWTH 154 10.4 HEALTHCARE PAYERS 155 10.4.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND 155 10.5 PUBLIC PAYERS 156 10.5.1 FOCUS ON ENHANCING PUBLIC PAYER DECISION-MAKING WITH RWE SOLUTIONS TO BOOST MARKET 156 10.6 PRIVATE PAYERS 157 10.6.1 NEED FOR LEVERAGING PRIVATE PAYERS FOR SUSTAINABLE RWE SOLUTIONS TO SPUR DEMAND 157 10.7 HEALTHCARE PROVIDERS 158 10.7.1 GROWING FOCUS ON IMPROVING PROFITABILITY TO SUPPORT MARKET GROWTH 158 10.7.2 HOSPITALS 159 10.7.3 CLINICS & OTHER OUTPATIENT SETTINGS 160 10.7.4 OTHER HEALTHCARE PROVIDERS 161 10.8 OTHER END USERS 161 11 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION 163 11.1 INTRODUCTION 164 11.2 NORTH AMERICA 164 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 164 11.2.2 US 169 11.2.2.1 US to account for significant share of North American market 169 11.2.3 CANADA 174 11.2.3.1 Increase in pharma hub growth in Canada to drive market 174 11.3 EUROPE 178 11.3.1 EUROPE: MACROECONOMIC OUTLOOK 178 11.3.2 GERMANY 183 11.3.2.1 High pharmaceutical R&D spending in Germany to boost market growth 183 11.3.3 UK 187 11.3.3.1 Growing adoption of HTA to support market growth 187 11.3.4 FRANCE 191 11.3.4.1 Need for extensive and diversified database to drive market growth 191 11.3.5 ITALY 195 11.3.5.1 High demand for RWE due to widespread use of pay-for-outcomes to drive market 195 11.3.6 SPAIN 199 11.3.6.1 Rising R&D expenditure to propel market growth 199 11.3.7 REST OF EUROPE 204 11.4 ASIA PACIFIC 209 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 209 11.4.2 JAPAN 214 11.4.2.1 Stringent regulatory scenario in Japan to restrain market growth 214 11.4.3 CHINA 218 11.4.3.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market 218 11.4.4 INDIA 223 11.4.4.1 Growing adoption of outcome-based research to drive market 223 11.4.5 AUSTRALIA 227 11.4.5.1 Policy reforms and strong regulations to support market growth 227 11.4.6 SOUTH KOREA 231 11.4.6.1 Increased focus on pharma R&D to boost market growth 231 11.4.7 REST OF ASIA PACIFIC 235 11.5 LATIN AMERICA 240 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 240 11.5.2 BRAZIL 244 11.5.2.1 Evolving regulatory frameworks that facilitate clinical research to drive market 244 11.5.3 MEXICO 248 11.5.3.1 Increased funding and investments in pharma R&D to favor growth 248 11.5.4 REST OF LATIN AMERICA 252 11.6 MIDDLE EAST & AFRICA 256 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 257 11.6.2 GCC COUNTRIES 261 11.6.2.1 Growing availability of healthcare funding to offer opportunities for market growth 261 11.6.2.2 Saudi Arabia 266 11.6.2.2.1 Digital health reform and regulatory innovation to offer opportunities for market growth 266 11.6.2.3 UAE 270 11.6.2.3.1 Need for driving data-driven healthcare transformation to boost market 270 11.6.2.4 Rest of GCC 274 11.6.3 SOUTH AFRICA 278 11.6.3.1 Emphasis on supporting healthcare infrastructure to drive market growth 278 11.6.4 REST OF MIDDLE EAST & AFRICA 282 12 COMPETITIVE LANDSCAPE 286 12.1 INTRODUCTION 286 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 286 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 286 12.3 REVENUE SHARE ANALYSIS 289 12.4 MARKET SHARE ANALYSIS 289 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 292 12.5.1 STARS 292 12.5.2 EMERGING LEADERS 292 12.5.3 PERVASIVE PLAYERS 292 12.5.4 PARTICIPANTS 292 12.5.5 COMPANY FOOTPRINT 294 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 299 12.6.1 PROGRESSIVE COMPANIES 299 12.6.2 RESPONSIVE COMPANIES 299 12.6.3 DYNAMIC COMPANIES 299 12.6.4 STARTING BLOCKS 299 12.6.5 COMPETITIVE BENCHMARKING 301 12.7 BRAND/PRODUCT COMPARISON 302 12.8 VALUATION AND FINANCIAL METRICS 302 12.9 COMPETITIVE SCENARIO 303 12.9.1 PRODUCT LAUNCHES/ENHANCEMENTS 303 12.9.2 DEALS 304 12.9.3 OTHER DEVELOPMENTS 305 13 COMPANY PROFILES 306 13.1 KEY PLAYERS 306 13.1.1 IQVIA 306 13.1.1.1 Business overview 306 13.1.1.2 Products offered 307 13.1.1.3 Recent developments 308 13.1.1.3.1 Deals 308 13.1.1.4 MnM view 309 13.1.1.4.1 Key strengths/Right to win 309 13.1.1.4.2 Strategic choices 309 13.1.1.4.3 Weaknesses and competitive threats 309 13.1.2 MERATIVE 310 13.1.2.1 Business overview 310 13.1.2.2 Products offered 310 13.1.2.3 Recent developments 311 13.1.2.3.1 Deals 311 13.1.2.3.2 Other developments 311 13.1.2.4 MnM view 312 13.1.2.4.1 Key strengths/Right to win 312 13.1.2.4.2 Strategic choices 312 13.1.2.4.3 Weaknesses and competitive threats 312 13.1.3 OPTUM, INC. 313 13.1.3.1 Business overview 313 13.1.3.2 Products offered 314 13.1.3.3 Recent developments 315 13.1.3.3.1 Product launches/developments 315 13.1.3.3.2 Deals 315 13.1.3.4 MnM view 316 13.1.3.4.1 Key strengths/Right to win 316 13.1.3.4.2 Strategic choices made 316 13.1.3.4.3 Weaknesses and competitive threats 316 13.1.4 ICON PLC 317 13.1.4.1 Business overview 317 13.1.4.2 Products offered 318 13.1.4.3 Recent developments 319 13.1.4.3.1 Product launches/developments 319 13.1.4.3.2 Deals 319 13.1.4.4 MnM view 320 13.1.4.4.1 Key strengths/Right to win 320 13.1.4.4.2 Strategic choices 320 13.1.4.4.3 Weaknesses and competitive threats 320 13.1.5 SYNEOS HEALTH 321 13.1.5.1 Business overview 321 13.1.5.2 Products offered 321 13.1.5.3 Recent developments 322 13.1.5.3.1 Deals 322 13.1.5.4 MnM view 323 13.1.5.4.1 Key strengths/Right to win 323 13.1.5.4.2 Strategic choices 323 13.1.5.4.3 Weaknesses and competitive threats 323 13.1.6 PAREXEL INTERNATIONAL (MA) CORPORATION 324 13.1.6.1 Business overview 324 13.1.6.2 Products offered 324 13.1.6.3 Recent developments 325 13.1.6.3.1 Product launches/developments 325 13.1.6.3.2 Deals 325 13.1.7 FLATIRON HEALTH 327 13.1.7.1 Business overview 327 13.1.7.2 Products offered 327 13.1.7.3 Recent developments 328 13.1.7.3.1 Product launches/developments 328 13.1.7.3.2 Deals 328 13.1.8 FORTREA 330 13.1.8.1 Business overview 330 13.1.8.2 Products offered 331 13.1.8.3 Recent developments 332 13.1.8.3.1 Product launches/developments 332 13.1.8.3.2 Deals 332 13.1.9 ORACLE 333 13.1.9.1 Business overview 333 13.1.9.2 Products offered 334 13.1.9.3 Recent developments 335 13.1.9.3.1 Product launches/developments 335 13.1.9.3.2 Deals 335 13.1.10 ELEVANCE HEALTH 337 13.1.10.1 Business overview 337 13.1.10.2 Products offered 338 13.1.11 SAS INSTITUTE INC. 339 13.1.11.1 Business overview 339 13.1.11.2 Products offered 339 13.1.11.3 Recent developments 340 13.1.11.3.1 Product launches/developments 340 13.1.12 AETION, INC. 341 13.1.12.1 Business overview 341 13.1.12.2 Products offered 341 13.1.12.3 Recent developments 342 13.1.12.3.1 Product launches/developments 342 13.1.12.3.2 Deals 342 13.1.13 TRINETX, LLC 344 13.1.13.1 Business overview 344 13.1.13.2 Products offered 344 13.1.13.3 Recent developments 345 13.1.13.3.1 Product launches/developments 345 13.1.13.3.2 Deals 345 13.1.14 TRINITY 347 13.1.14.1 Business overview 347 13.1.14.2 Products offered 347 13.1.14.3 Recent developments 348 13.1.14.3.1 Deals 348 13.1.15 MEDIDATA 349 13.1.15.1 Business overview 349 13.1.15.2 Products offered 349 13.1.15.3 Recent developments 350 13.1.15.3.1 Product launches/developments 350 13.1.15.3.2 Deals 350 13.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION 352 13.1.16.1 Business overview 352 13.1.16.2 Products offered 353 13.1.17 CEGEDIM HEALTH DATA 354 13.1.17.1 Business overview 354 13.1.17.2 Products offered 355 13.1.17.3 Recent developments 355 13.1.17.3.1 Product launches/developments 355 13.1.17.3.2 Deals 355 13.1.18 VERANTOS 356 13.1.18.1 Business overview 356 13.1.18.2 Products offered 356 13.1.18.3 Recent developments 357 13.1.18.3.1 Product launches/developments 357 13.1.18.3.2 Deals 358 13.1.19 MEDPACE 359 13.1.19.1 Business overview 359 13.1.19.2 Products offered 360 13.1.20 TATA CONSULTANCY SERVICES LIMITED 361 13.1.20.1 Business overview 361 13.1.20.2 Products offered 362 13.1.20.3 Recent developments 363 13.1.20.3.1 Deals 363 13.2 OTHER PLAYERS 364 13.2.1 HEALTHVERITY, INC. 364 13.2.2 OM1 364 13.2.3 OPEN HEALTH 365 13.2.4 TEMPUS 366 13.2.5 QUANTZIG 366 14 APPENDIX 367 14.1 DISCUSSION GUIDE 367 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 373 14.3 CUSTOMIZATION OPTIONS 375 14.4 RELATED REPORTS 375 14.5 AUTHOR DETAILS 376

TABLE 1 RISK ASSESSMENT ANALYSIS 52 TABLE 2 MARKET DYNAMICS: IMPACT ANALYSIS 65 TABLE 3 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES 77 TABLE 4 REAL WORLD EVIDENCE SOLUTIONS MARKET: ROLE OF PLAYERS IN ECOSYSTEM 81 TABLE 5 PORTER’S FIVE FORCES ANALYSIS 85 TABLE 6 INDICATIVE PRICING ANALYSIS OF REAL WORLD EVIDENCE SOLUTIONS, BY DATA SET, 2024 (USD) 87 TABLE 7 INDICATIVE PRICE RANGE OF REAL WORLD EVIDENCE SOLUTIONS, BY KEY REGION, 2024 (USD) 89 TABLE 8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 9 JURISDICTION ANALYSIS OF TOP APPLICANTS 98 TABLE 10 LIST OF PATENTS, 2017–2025 100 TABLE 11 DETAILED LIST OF CONFERENCES AND EVENTS 101 TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS 103 TABLE 13 KEY BUYING CRITERIA FOR KEY APPLICATIONS 103 TABLE 14 UNMET NEEDS IN REAL WORLD EVIDENCE SOLUTIONS MARKET 105 TABLE 15 END USER EXPECTATIONS IN REAL WORLD EVIDENCE SOLUTIONS MARKET 106 TABLE 16 RECIPROCAL TARIFF RATES ADJUSTED BY US 114 TABLE 17 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 119 TABLE 18 REAL WORLD EVIDENCE SERVICES OFFERED BY KEY MARKET PLAYERS 120 TABLE 19 REAL WORLD EVIDENCE SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 20 REAL WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2030 (USD MILLION) 121 TABLE 21 REAL WORLD EVIDENCE DATA SETS MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 22 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 122 TABLE 23 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 24 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS 123 TABLE 25 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 26 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS 124 TABLE 27 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 28 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 29 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS 125 TABLE 30 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 31 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 32 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER DATA SETS, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 33 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS 128 TABLE 34 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 35 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 130 TABLE 36 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 131 TABLE 37 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 38 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 39 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 40 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 41 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 42 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 43 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 44 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 45 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 46 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 47 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 48 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 49 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 144 TABLE 50 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USAGE (VALUE-BASED PRICING) MODEL, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 51 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODEL, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 52 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR LICENSE MODEL, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 53 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 149 TABLE 54 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISES MODE, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 55 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODE, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 56 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HYBRID MODE, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 57 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 153 TABLE 58 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 59 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 60 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 61 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 62 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PUBLIC PAYERS, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 63 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PRIVATE PAYERS, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 64 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 65 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 66 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 67 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICS & OTHER OUTPATIENT SETTINGS, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 68 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 69 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 70 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 71 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 72 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 166 TABLE 73 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 74 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 75 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 167 TABLE 76 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 77 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 168 TABLE 78 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 168 TABLE 79 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 80 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 169 TABLE 81 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 169 TABLE 82 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 170 TABLE 83 US: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 84 US: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 85 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 171 TABLE 86 US: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 87 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 172 TABLE 88 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 172 TABLE 89 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 173 TABLE 90 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 173 TABLE 91 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 173 TABLE 92 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 174 TABLE 93 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 94 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 95 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 175 TABLE 96 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 97 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 176 TABLE 98 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 176 TABLE 99 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 177 TABLE 100 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 177 TABLE 101 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 177 TABLE 102 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 103 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 179 TABLE 104 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 105 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 106 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 180 TABLE 107 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 108 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 181 TABLE 109 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 181 TABLE 110 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 182 TABLE 111 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 182 TABLE 112 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 182 TABLE 113 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 183 TABLE 114 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 115 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 116 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 185 TABLE 117 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 118 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 186 TABLE 119 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 186 TABLE 120 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 121 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 187 TABLE 122 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 187 TABLE 123 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 188 TABLE 124 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 125 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 126 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 189 TABLE 127 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 128 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 190 TABLE 129 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 190 TABLE 130 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 131 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 191 TABLE 132 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 191 TABLE 133 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 192 TABLE 134 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 135 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 136 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 193 TABLE 137 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 138 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 194 TABLE 139 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 194 TABLE 140 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 194 TABLE 141 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 195 TABLE 142 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 195 TABLE 143 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 196 TABLE 144 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 145 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 146 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 197 TABLE 147 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 148 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 198 TABLE 149 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 198 TABLE 150 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 198 TABLE 151 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 199 TABLE 152 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 199 TABLE 153 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 200 TABLE 154 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 155 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 156 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 201 TABLE 157 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 158 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 202 TABLE 159 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 202 TABLE 160 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 161 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 203 TABLE 162 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 203 TABLE 163 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 204 TABLE 164 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 165 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 166 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 167 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 206 TABLE 168 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 207 TABLE 169 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 207 TABLE 170 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 207 TABLE 171 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 208 TABLE 172 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 208 TABLE 173 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 210 TABLE 174 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 211 TABLE 175 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 176 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 177 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 178 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 212 TABLE 179 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 213 TABLE 180 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 213 TABLE 181 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 182 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 214 TABLE 183 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 214 TABLE 184 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 215 TABLE 185 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 215 TABLE 186 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 215 TABLE 187 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216 TABLE 188 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 216 TABLE 189 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 217 TABLE 190 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 217 TABLE 191 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 217 TABLE 192 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 218 TABLE 193 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 218 TABLE 194 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 219 TABLE 195 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 219 TABLE 196 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 197 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 220 TABLE 198 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 221 TABLE 199 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 221 TABLE 200 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 221 TABLE 201 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 222 TABLE 202 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 222 TABLE 203 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 222 TABLE 204 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 223 TABLE 205 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 206 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 207 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 225 TABLE 208 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 225 TABLE 209 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 226 TABLE 210 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 226 TABLE 211 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 212 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 227 TABLE 213 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 227 TABLE 214 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 228 TABLE 215 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 216 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 217 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 229 TABLE 218 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229 TABLE 219 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 230 TABLE 220 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 230 TABLE 221 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 222 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 231 TABLE 223 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 231 TABLE 224 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 232 TABLE 225 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 226 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 227 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 233 TABLE 228 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 233 TABLE 229 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 234 TABLE 230 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 234 TABLE 231 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 232 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 235 TABLE 233 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 235 TABLE 234 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 236 TABLE 235 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 236 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 237 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 238 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 237 TABLE 239 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 238 TABLE 240 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 238 TABLE 241 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 242 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 239 TABLE 243 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 239 TABLE 244 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 240 TABLE 245 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 241 TABLE 246 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 247 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 248 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 249 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 242 TABLE 250 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 243 TABLE 251 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 243 TABLE 252 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 243 TABLE 253 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 244 TABLE 254 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 244 TABLE 255 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 245 TABLE 256 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 257 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 245 TABLE 258 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 259 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 246 TABLE 260 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 247 TABLE 261 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 247 TABLE 262 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 263 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 248 TABLE 264 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 248 TABLE 265 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 249 TABLE 266 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 267 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 268 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 250 TABLE 269 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250 TABLE 270 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 251 TABLE 271 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 251 TABLE 272 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 273 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 252 TABLE 274 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 252 TABLE 275 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 252 TABLE 276 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 277 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 278 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 254 TABLE 279 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 254 TABLE 280 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 255 TABLE 281 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 255 TABLE 282 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 255 TABLE 283 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 256 TABLE 284 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 256 TABLE 285 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 257 TABLE 286 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 257 TABLE 287 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 288 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 289 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 259 TABLE 290 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 259 TABLE 291 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 260 TABLE 292 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 260 TABLE 293 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 260 TABLE 294 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 261 TABLE 295 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 261 TABLE 296 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 262 TABLE 297 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 262 TABLE 298 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 299 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 300 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 263 TABLE 301 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 264 TABLE 302 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 264 TABLE 303 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 264 TABLE 304 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 265 TABLE 305 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 265 TABLE 306 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 265 TABLE 307 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 266 TABLE 308 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 309 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 267 TABLE 310 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 311 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 268 TABLE 312 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 268 TABLE 313 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 268 TABLE 314 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 315 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 269 TABLE 316 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 269 TABLE 317 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 270 TABLE 318 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 319 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 320 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 271 TABLE 321 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 272 TABLE 322 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 272 TABLE 323 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 272 TABLE 324 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 273 TABLE 325 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 273 TABLE 326 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 273 TABLE 327 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 274 TABLE 328 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 329 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 330 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 275 TABLE 331 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 276 TABLE 332 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 276 TABLE 333 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 276 TABLE 334 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 277 TABLE 335 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 277 TABLE 336 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 277 TABLE 337 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 278 TABLE 338 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 339 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 279 TABLE 340 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 279 TABLE 341 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 280 TABLE 342 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 280 TABLE 343 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 280 TABLE 344 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 281 TABLE 345 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 281 TABLE 346 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 281 TABLE 347 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 282 TABLE 348 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 349 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 283 TABLE 350 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 283 TABLE 351 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 284 TABLE 352 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 284 TABLE 353 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 284 TABLE 354 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 285 TABLE 355 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 285 TABLE 356 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 285 TABLE 357 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022–JULY 2025 286 TABLE 358 REAL WORLD EVIDENCE SOLUTIONS MARKET: DEGREE OF COMPETITION 290 TABLE 359 REGIONAL FOOTPRINT 295 TABLE 360 COMPONENT FOOTPRINT 296 TABLE 361 END USER FOOTPRINT 297 TABLE 362 APPLICATION FOOTPRINT 298 TABLE 363 REAL WORLD EVIDENCE SOLUTIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 301 TABLE 364 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 301 TABLE 365 REAL WORLD EVIDENCE SOLUTIONS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, JANUARY 2022–JULY 2025 303 TABLE 366 REAL WORLD EVIDENCE SOLUTIONS MARKET: DEALS, JANUARY 2022–JULY 2025 304 TABLE 367 REAL WORLD EVIDENCE SOLUTIONS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025 305 TABLE 368 IQVIA: COMPANY OVERVIEW 306 TABLE 369 IQVIA: PRODUCTS OFFERED 307 TABLE 370 IQVIA: DEALS, JANUARY 2022–JULY 2025 308 TABLE 371 MERATIVE: COMPANY OVERVIEW 310 TABLE 372 MERATIVE: PRODUCTS OFFERED 310 TABLE 373 MERATIVE: DEALS, JANUARY 2022–JULY 2025 311 TABLE 374 MERATIVE: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025 311 TABLE 375 OPTUM, INC.: COMPANY OVERVIEW 313 TABLE 376 OPTUM, INC.: PRODUCTS OFFERED 314 TABLE 377 OPTUM, INC.: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 315 TABLE 378 OPTUM, INC. DEALS, JANUARY 2022–JULY 2025 315 TABLE 379 ICON PLC: COMPANY OVERVIEW 317 TABLE 380 ICON PLC: PRODUCTS OFFERED 318 TABLE 381 ICON PLC: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 319 TABLE 382 ICON PLC: DEALS, JANUARY 2022–JULY 2025 319 TABLE 383 SYNEOS HEALTH: COMPANY OVERVIEW 321 TABLE 384 SYNEOS HEALTH: PRODUCTS OFFERED 321 TABLE 385 SYNEOS HEALTH: DEALS, JANUARY 2022–JULY 2025 322 TABLE 386 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW 324 TABLE 387 PAREXEL INTERNATIONAL (MA) CORPORATION: PRODUCTS OFFERED 324 TABLE 388 PAREXEL INTERNATIONAL (MA) CORPORATION: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 325 TABLE 389 PAREXEL INTERNATIONAL (MA) CORPORATION: DEALS, JANUARY 2022–JULY 2025 325 TABLE 390 FLATIRON HEALTH: COMPANY OVERVIEW 327 TABLE 391 FLATIRON HEALTH: PRODUCTS OFFERED 327 TABLE 392 FLATIRON HEALTH: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 328 TABLE 393 FLATIRON HEALTH: DEALS, JANUARY 2022–JULY 2025 328 TABLE 394 FORTREA: COMPANY OVERVIEW 330 TABLE 395 FORTREA: PRODUCTS OFFERED 331 TABLE 396 FORTREA: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 332 TABLE 397 FORTREA: DEALS, JANUARY 2022–JULY 2025 332 TABLE 398 ORACLE: COMPANY OVERVIEW 333 TABLE 399 ORACLE: PRODUCTS OFFERED 334 TABLE 400 ORACLE: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 335 TABLE 401 ORACLE: DEALS, JANUARY 2022–JULY 2025 335 TABLE 402 ELEVANCE HEALTH: COMPANY OVERVIEW 337 TABLE 403 ELEVANCE HEALTH: PRODUCTS OFFERED 338 TABLE 404 SAS INSTITUTE INC.: COMPANY OVERVIEW 339 TABLE 405 SAS INSTITUTE INC.: PRODUCTS OFFERED 339 TABLE 406 SAS INSTITUTE INC.: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 340 TABLE 407 AETION, INC.: COMPANY OVERVIEW 341 TABLE 408 AETION, INC.: PRODUCTS OFFERED 341 TABLE 409 AETION, INC.: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 342 TABLE 410 AETION, INC.: DEALS, JANUARY 2022–JULY 2025 342 TABLE 411 TRINETX, LLC: COMPANY OVERVIEW 344 TABLE 412 TRINETX, LLC: PRODUCTS OFFERED 344 TABLE 413 TRINETX, LLC: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 345 TABLE 414 TRINETX, LLC: DEALS, JANUARY 2022–JULY 2025 345 TABLE 415 TRINITY: COMPANY OVERVIEW 347 TABLE 416 TRINITY: PRODUCTS OFFERED 347 TABLE 417 TRINITY: DEALS, JANUARY 2022–JULY 2025 348 TABLE 418 MEDIDATA: COMPANY OVERVIEW 349 TABLE 419 MEDIDATA: PRODUCTS OFFERED 349 TABLE 420 MEDIDATA: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 350 TABLE 421 MEDIDATA: DEALS, JANUARY 2022–JULY 2025 350 TABLE 422 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY OVERVIEW 352 TABLE 423 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: PRODUCTS OFFERED 353 TABLE 424 CEGEDIM HEALTH DATA: COMPANY OVERVIEW 354 TABLE 425 CEGEDIM HEALTH DATA: PRODUCTS OFFERED 355 TABLE 426 CEGEDIM HEALTH DATA: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 355 TABLE 427 CEGEDIM HEALTH DATA: DEALS, JANUARY 2022–JULY 2025 355 TABLE 428 VERANTOS: COMPANY OVERVIEW 356 TABLE 429 VERANTOS: PRODUCTS OFFERED 356 TABLE 430 VERANTOS: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 357 TABLE 431 VERANTOS: DEALS, JANUARY 2022–JULY 2025 358 TABLE 432 MEDPACE: COMPANY OVERVIEW 359 TABLE 433 MEDPACE: PRODUCTS OFFERED 360 TABLE 434 TATA CONSULTANCY SERVICES LIMITED: COMPANY OVERVIEW 361 TABLE 435 TATA CONSULTANCY SERVICES LIMITED: PRODUCTS OFFERED 362 TABLE 436 TATA CONSULTANCY SERVICES LIMITED: DEALS, JANUARY 2022–JULY 2025 363 TABLE 437 HEALTHVERITY, INC.: COMPANY OVERVIEW 364 TABLE 438 OM1: COMPANY OVERVIEW 364 TABLE 439 OPEN HEALTH: COMPANY OVERVIEW 365 TABLE 440 TEMPUS: COMPANY OVERVIEW 366 TABLE 441 QUANTZIG: COMPANY OVERVIEW 366 FIGURE 1 RESEARCH DESIGN 40 FIGURE 2 PRIMARY SOURCES 43 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 45 FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 46 FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 47 FIGURE 6 BOTTOM-UP APPROACH 48 FIGURE 7 TOP-DOWN APPROACH 48 FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2024–2030 49 FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 50 FIGURE 10 DATA TRIANGULATION METHODOLOGY 51 FIGURE 11 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2025 VS. 2030 (USD MILLION) 54 FIGURE 12 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2025 VS. 2030 (USD MILLION) 55 FIGURE 13 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2025 VS. 2030 (USD MILLION) 55 FIGURE 14 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 56 FIGURE 15 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 57 FIGURE 16 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2025 VS. 2030 (USD MILLION) 57 FIGURE 17 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2025 VS. 2030 (USD MILLION) 58 FIGURE 18 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 58 FIGURE 19 REAL WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 59 FIGURE 20 RISING GERIATRIC POPULATION AND SUBSEQUENT INCREASE IN PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 60 FIGURE 21 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024 61 FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 62 FIGURE 23 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 62 FIGURE 24 EMERGING ECONOMIES TO REGISTER SIGNIFICANT GROWTH DURING FORECAST PERIOD 63 FIGURE 25 REAL WORLD EVIDENCE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64 FIGURE 26 NUMBER OF CLINICAL TRIALS ACROSS REGIONS, 2022–2024 68 FIGURE 27 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE 75 FIGURE 28 RWE ANALYTICS APPROACH: INTERNAL VS. OUTSOURCED 76 FIGURE 29 ECOSYSTEM ANALYSIS 80 FIGURE 30 REAL WORLD EVIDENCE SOLUTIONS MARKET: VALUE CHAIN ANALYSIS 82 FIGURE 31 REVENUE SHIFT IN REAL WORLD EVIDENCE SOLUTIONS MARKET 84 FIGURE 32 PORTER’S FIVE FORCES ANALYSIS 85 FIGURE 33 JURISDICTION AND TOP APPLICANT ANALYSIS 98 FIGURE 34 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2015 TO JULY 2025 99 FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS 102 FIGURE 36 KEY BUYING CRITERIA FOR KEY APPLICATIONS 103 FIGURE 37 INVESTMENT & FUNDING SCENARIO 108 FIGURE 38 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING REAL WORLD EVIDENCE SOLUTIONS ACROSS INDUSTRIES 109 FIGURE 39 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT MARKET ECOSYSTEM 111 FIGURE 40 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT 165 FIGURE 41 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT 210 FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 (USD MILLION) 289 FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 290 FIGURE 44 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 293 FIGURE 45 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPANY FOOTPRINT 294 FIGURE 46 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 300 FIGURE 47 BRAND/PRODUCT COMPARISON 302 FIGURE 48 EV/EBITDA OF KEY VENDORS 302 FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF REAL WORLD EVIDENCE SOLUTIONS, 2024 303 FIGURE 50 IQVIA: COMPANY SNAPSHOT (2024) 307 FIGURE 51 OPTUM, INC.: COMPANY SNAPSHOT (2024) 314 FIGURE 52 ICON PLC: COMPANY SNAPSHOT (2024) 318 FIGURE 53 FORTREA: COMPANY SNAPSHOT (2024) 331 FIGURE 54 ORACLE: COMPANY SNAPSHOT (2024) 334 FIGURE 55 ELEVANCE HEALTH: COMPANY SNAPSHOT (2024) 337 FIGURE 56 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2024) 353 FIGURE 57 CEGEDIM HEALTH DATA: COMPANY SNAPSHOT (2024) 354 FIGURE 58 MEDPACE: COMPANY SNAPSHOT (2024) 359 FIGURE 59 TATA CONSULTANCY SERVICES LIMITED.: COMPANY SNAPSHOT (2024) 362

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

Real World Evidence Solutions Market by Component (Datasets (Claims, Clinical, Pharmacy, Genomics), Application (Drug/Device Development (Cancer, Cardio, Neuro), Reimbursement), End User (Pharma, Medtech, Payers, Provider), Region - Global Forecast to 2030

授權報價

報告摘要

同分類最新報告（醫療與生命科學）